PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
admin 24th October 2018 Uncategorised 0The red-hot class of PARP inhibitors showed up at this weekend’s European Society for Medical Oncology annual meeting, posting important—and impressive—data in multiple tumor types. But despite four drugs and a wealth of studies supporting them, some doctors haven’t jumped on board.
More: PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Source: fierce